Morning! With your regular correspondent due to fly out on holiday in just a few short days, this is the last Monday Morning Briefing of September. Better make it a good one, then. As always, don’t forget to comment, like, and share with your colleagues, and we’ll meet again when I return.
Good morning! We trust you had a happy and safe Labor Day weekend. Sadly, it’s time for the labor to get underway once more, so ease yourself into the week by getting up-to-date with the week’s pharma headlines.
Morning! This week’s pharma roundup has much less in the way of Kim Kardashian news (more’s the pity, right?) and more in the way of pharmaceutical dealmaking, new drug technology, and approval analysis. Read on, and be enlightened.
G’day! Would you like the good news first? It’s Monday morning, meaning another working week is upon us. Excellent! The bad? Well, we only have five days of it until the inevitable blasted weekend. Let’s make the most of it while we can, then, and let’s kick things off with the week’s top five pharma headlines.
Good Morning! We hope you had an enjoyable holiday weekend and managed to wring every last bit of fun out of those four glorious days. Of course, you’ll have been far too busy having fun to keep up with the latest developments on Planet Pharma, so we’ve been trawling the weekend’s news to bring them to you. Enjoy!
Good morning, readers! Truth be told, there’s been more discussion of Don Draper than drug development in the Formedix office this morning, but it hasn't stopped us getting through the weekend’s latest pharmaceutical news. Here are the five stories from the last week that are distracting us from a marathon Mad Men mull-over:
Good morning! And, for once, I really mean it. It is a good morning here, where the sun is splitting the sky, the coffee was freshly-brewed when I reached the office, and there’s a veritable slew of industry news to wade through. Now, without any further ado, let’s get your Monday kick-started:
We’re celebrating the 15th Anniversary of Formedix this year. It got us thinking about how the clinical trials world has changed since we've been around: sometimes it feels like little has changed in 15 years, but often it feels like the pace of change is unsustainable. This is the last in our three-part series - part one is here, and part two is here. Read on for the final installment of our top 15 things that have changed in clinical trials since 2000.